Sharedwww / copyright / DHaank.txtOpen in CoCalc
Author: William A. Stein
1
2
3
July 2001
4
5
Dear Editor,
6
7
With the news just released that Reed Elsevier�s acquisition of the
8
Harcourt publishing businesses has been approved by the competition
9
authorities in the US and UK, we wanted to inform you immediately
10
about our plans. For Elsevier Science this means that we will bring
11
the Harcourt scientific, technical and medical (STM) publishing and
12
our existing businesses together as one. We are delighted about this
13
and intend to ensure that it means improved products and services and
14
increased value for scientists and libraries. I would like to give
15
you some insight into how we will do this.
16
17
The combined business will focus entirely on scientific, technical and
18
medical publishing. We believe that Harcourt STM and Elsevier Science
19
are an excellent match in terms of culture and business. The products
20
and people in the Harcourt scientific, technical and medical
21
publishing businesses reflect the Elsevier Science commitment to
22
quality and value.
23
24
The name of our combined business will be Elsevier Science. We have
25
created two divisions: Science & Technology and Health Sciences, both
26
operating under the Elsevier Science name. In the Science &
27
Technology Division we will add the journals, books and major
28
reference works published under the Academic Press imprint to our
29
existing portfolio. In addition to existing Elsevier Science products
30
and imprints, such as The Lancet and Excerpta Medica, the Health
31
Sciences Division will include the well-known imprints of
32
W.B. Saunders, Mosby and Churchill Livingstone, as well as MD Consult.
33
34
Our business strategy will continue as before. We want your
35
publications to be as widely accessible and widely-read as possible.
36
Our mission is to make all of our scientific material available to
37
researchers on their desktops, 24 hours a day, wherever they are in
38
the world.
39
40
We will retain the integrity and editorial independence of all
41
journals. We will not close down any journals as a direct result of
42
the merger. Contracts with editors and authors in general will not
43
change.
44
45
Our market-leading electronic platform, ScienceDirect�, is evidence of
46
our commitment to invest in quality products. We will continue these
47
investments in the combined business. The first step is to create
48
access through ScienceDirect to all the journal titles from the
49
Harcourt portfolio as soon as possible. This will enable the widest
50
possible access to your journal. Elsevier Science will also honour
51
all existing contracts for the IDEAL platform.
52
53
The commitment we made two years ago to keeping price rises to a
54
single digit figure for the complete print package of our journals,
55
incorporating the effects of currency fluctuations, growth in volume
56
output and inflation, will also apply to the extended portfolio. This
57
should result in lower price increases for Harcourt journals than in
58
the past and also below the industry average, in line with Elsevier
59
Science�s policy.
60
61
Over the coming months we will keep you informed about the progress
62
being made in bringing together the competencies and people of
63
Harcourt and Elsevier Science.
64
65
Scientific publishing is going through a period of rapid change as a
66
result of electronic publishing. At Elsevier Science we are very
67
excited about the possibilities it offers to enhance the role that
68
scientific literature plays in the research process. I enclose the
69
transcript of a presentation I made earlier this year, which should
70
give you a flavour of our current thinking on how we can move forward
71
to reap the full benefits of electronic publishing.
72
73
I would like to thank you for your work and dedication on your
74
journal. If you have any further questions, please do not hesitate to
75
ask your regular contacts at Elsevier Science and Harcourt.
76
77
Yours sincerely,
78
79
Derk Haank
80
Chairman
81
Elsevier Science